Drug intelligence / Profile preview

BNSO-3

Development stage: Preclinical
Lead developer: BNS Ophthalmics
Modality: Small Molecules
Administration: Topical

Overview

BNSO-3 is a novel topical ophthalmic drug candidate developed by BNS Ophthalmics for the treatment of dry eye disease. It leverages nanotechnology-based delivery, likely an ocular emulsion formulation, to address unmet needs in this multibillion-dollar market. As part of BNS Ophthalmics' pipeline, it follows BNSO-1 (for chronic anterior uveitis) and targets symptomatic relief through localized anti-inflammatory or moisturizing effects, though specific mechanism details remain undisclosed pending clinical data.[19][22]

Beyond the preview

Go deeper on BNSO-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BNSO-3.

Explore the full profile